Par Drugs And Chemicals Limited - Asset Resilience Ratio
Par Drugs And Chemicals Limited (PAR) has an Asset Resilience Ratio of 3.08% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Par Drugs And Chemicals Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Par Drugs And Chemicals Limited's Asset Resilience Ratio has changed over time. See Par Drugs And Chemicals Limited shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Par Drugs And Chemicals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Par Drugs And Chemicals Limited (PAR) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs31.31 Million | 3.08% |
| Total Liquid Assets | Rs31.31 Million | 3.08% |
Asset Resilience Insights
- Limited Liquidity: Par Drugs And Chemicals Limited maintains only 3.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Par Drugs And Chemicals Limited Industry Peers by Asset Resilience Ratio
Compare Par Drugs And Chemicals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Par Drugs And Chemicals Limited (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Par Drugs And Chemicals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 0.00% | Rs1.00K ≈ $10.81 |
Rs1.02 Billion ≈ $10.99 Million |
-3.38pp |
| 2023-03-31 | 3.38% | Rs30.02 Million ≈ $324.61K |
Rs888.68 Million ≈ $9.61 Million |
+2.10pp |
| 2022-03-31 | 1.27% | Rs10.02 Million ≈ $108.32K |
Rs786.90 Million ≈ $8.51 Million |
+1.27pp |
| 2019-03-31 | 0.00% | Rs150.00 ≈ $1.62 |
Rs513.55 Million ≈ $5.55 Million |
-- |
About Par Drugs And Chemicals Limited
Par Drugs and Chemicals Limited develops, manufactures, and sells active pharmaceutical ingredients (APIs) and fine chemicals in India. The company provides API products, including magnesium hydroxide, magnesium oxide USP, sucralfate, almagate BP, dried aluminium hydroxide gel, light magnesium carbonate, magaldrate, magnesium trisilicate, colloidal silicon dioxide, aluminium magnesium silicate, m… Read more